<DOC>
	<DOCNO>NCT03006614</DOCNO>
	<brief_summary>This study aim explore new PERS prediction model improve pathological complete response rate neoadjuvant chemotherapy breast cancer disease-free survival .</brief_summary>
	<brief_title>PERS Genetic Model Assistant Decision-making System Neoadjuvant Chemotherapy Breast Cancer</brief_title>
	<detailed_description>This multi-center , prospective , randomized phase III clinical trial . Planning 320 case . This study divide two stage . Phase one , 120 case local advance breast cancer ( LABC ) need neoadjuvant chemotherapy . Gene prediction model test ( PERS ) perform treatment ( ddEC-T+/-H ) , verify prediction efficacy PERS . Phase two , 200 case LABC primary resistant antharcycline taxans . Patients randomized Arm ddEC-T+/-H Arm PERS ( regimens accord PERS , eg NVB+DDP , capacitabine , gemcitabine ) pCR rate DFS observe .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Inclusion criterion : patient trial need meet age : least 18 year old ; ECOG ( Eastern Cooperative Oncology Group ) score ≤1 ; confirm histology cytology breast infiltrate ductal carcinoma agree breast cancer tissue biopsy new adjuvant chemotherapy patient stage II/III According RECIST criterion , target lesion patient least one , least one single diameter measurable lesion .Is define measurable lesion follow method accurately measure least one diameter lesion : lesion great diameter 20 mm measure conventional method spiral CT measurement lesion 10 mm diameter great . Positron emission tomography ( CT ) ultrasound use measurement method lesion . The normal numerical laboratory： The patient 's level organ function must meet following requirement : enough reserve : bone marrow neutrophil ( cent leave ribbon neutrophil ) absolute count ( ANC ) ≥1.5*109 / L , platelets≥ 100*109 / L , acuity ≥ 9 g/dL hemoglobin.Liver : bilirubin &lt; 1.5 time upper limit normal , alkaline phosphatase ( AP ) , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 3.0 time upper limit normal ( If allow AP liver metastasis , AST , ALT &lt; 5 time upper limit normal ) .Kidney： creatinine clearance 45 mL/min . Signed informed consent ; expect survival patient 3 month . patient adherence geographic location residence meet need followup . research group 7 day serum urine pregnancy test must negative , must nurse patients.Or sterilization surgery , patient menopause , agree research treatment research within 6 month end treatment period use approve medical contraception ( intrauterine device ( IUD ) , pill condom ) ECOG ( Eastern Cooperative Oncology Group ) score ≥2 ; At time accept antitumor treatment . In past 12 month congestive heart failure , drug treatment ca n't control history arrhythmia , myocardial infarction , etc ; The serious , controlled intercurrent infection , organ dysfunction , serious metabolic disorder patient ; Active infection ( decided researcher . According researcher 's judgment , serious endanger safety patient , patient complete research associate disease . Pregnancy breastfeed woman . Always clear history neurological psychiatric disorder , include epilepsy , dementia . A history tumor combine tumor patient . Before study enrollment reason within 30 day use approved local drug ； Unwilling unable continue comply experimental program , cope patient followup ; Researchers think unfavorable participant .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Breast Cancer Model</keyword>
	<keyword>Effects Chemotherapy</keyword>
	<keyword>breast cancer</keyword>
</DOC>